Rezpegaldesleukin

DRUG5 trials

Sponsors

Nektar Therapeutics, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Alopecia AreataModerate to Severe Atopic DermatitisModerate-to-Severe Atopic DermatitisType 1 Diabetes Mellitus

Phase 2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Active, not recruitingNCT06136741

Nektar TherapeuticsModerate to Severe Atopic Dermatitis

Start: 2023-11-15End: 2026-12-31Target: 396Updated: 2026-08-21

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

CompletedNCT06340360

Nektar TherapeuticsAlopecia Areata

Start: 2024-04-02End: 2026-08-20Updated: 2026-09-18

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

RecruitingNCT07142252

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Type 1 Diabetes Mellitus

Start: 2026-05-14End: 2028-05-25Target: 66Updated: 2026-09-08

Phase 3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07690371

Nektar TherapeuticsModerate-to-Severe Atopic Dermatitis

Start: 2026-06-29End: 2028-12-01Target: 510Updated: 2026-09-14

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07711418

Nektar TherapeuticsModerate-to-Severe Atopic Dermatitis

Start: 2026-08-07End: 2029-01-01Target: 510Updated: 2026-09-08

Related Papers

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

2026-08-21

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

2024-10-2516 citations

Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases

Allergy2024-08-162 citations

729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis

British Journal of Dermatology2024-08-011 citations

724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

British Journal of Dermatology2024-08-01